JP2020050677A5 - - Google Patents

Download PDF

Info

Publication number
JP2020050677A5
JP2020050677A5 JP2020000194A JP2020000194A JP2020050677A5 JP 2020050677 A5 JP2020050677 A5 JP 2020050677A5 JP 2020000194 A JP2020000194 A JP 2020000194A JP 2020000194 A JP2020000194 A JP 2020000194A JP 2020050677 A5 JP2020050677 A5 JP 2020050677A5
Authority
JP
Japan
Prior art keywords
composition
antibody
cancer
combination
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020000194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020050677A (ja
JP6833080B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020050677A publication Critical patent/JP2020050677A/ja
Publication of JP2020050677A5 publication Critical patent/JP2020050677A5/ja
Application granted granted Critical
Publication of JP6833080B2 publication Critical patent/JP6833080B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020000194A 2014-10-29 2020-01-06 非フコシル化抗ｃｄ４０抗体の投与量および投与 Expired - Fee Related JP6833080B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462072031P 2014-10-29 2014-10-29
US62/072,031 2014-10-29
US201562134955P 2015-03-18 2015-03-18
US62/134,955 2015-03-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017522840A Division JP6691113B2 (ja) 2014-10-29 2015-10-29 非フコシル化抗ｃｄ４０抗体の投与量および投与

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020150669A Division JP7165166B2 (ja) 2014-10-29 2020-09-08 非フコシル化抗ｃｄ４０抗体の投与量および投与

Publications (3)

Publication Number Publication Date
JP2020050677A JP2020050677A (ja) 2020-04-02
JP2020050677A5 true JP2020050677A5 (https=) 2020-10-22
JP6833080B2 JP6833080B2 (ja) 2021-02-24

Family

ID=55858352

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017522840A Expired - Fee Related JP6691113B2 (ja) 2014-10-29 2015-10-29 非フコシル化抗ｃｄ４０抗体の投与量および投与
JP2020000194A Expired - Fee Related JP6833080B2 (ja) 2014-10-29 2020-01-06 非フコシル化抗ｃｄ４０抗体の投与量および投与
JP2020150669A Active JP7165166B2 (ja) 2014-10-29 2020-09-08 非フコシル化抗ｃｄ４０抗体の投与量および投与
JP2021039216A Withdrawn JP2021088609A (ja) 2014-10-29 2021-03-11 非フコシル化抗ｃｄ４０抗体の投与量および投与
JP2023114493A Pending JP2023126406A (ja) 2014-10-29 2023-07-12 非フコシル化抗ｃｄ４０抗体の投与量および投与

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017522840A Expired - Fee Related JP6691113B2 (ja) 2014-10-29 2015-10-29 非フコシル化抗ｃｄ４０抗体の投与量および投与

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020150669A Active JP7165166B2 (ja) 2014-10-29 2020-09-08 非フコシル化抗ｃｄ４０抗体の投与量および投与
JP2021039216A Withdrawn JP2021088609A (ja) 2014-10-29 2021-03-11 非フコシル化抗ｃｄ４０抗体の投与量および投与
JP2023114493A Pending JP2023126406A (ja) 2014-10-29 2023-07-12 非フコシル化抗ｃｄ４０抗体の投与量および投与

Country Status (21)

Country Link
US (8) US11213584B2 (https=)
EP (2) EP3212230B1 (https=)
JP (5) JP6691113B2 (https=)
KR (2) KR20240073140A (https=)
CN (2) CN114522228A (https=)
AU (2) AU2015339128C1 (https=)
BR (1) BR112017008959A2 (https=)
CA (1) CA2963720C (https=)
CY (1) CY1124033T1 (https=)
DK (1) DK3212230T3 (https=)
EA (1) EA036498B1 (https=)
ES (1) ES2864756T3 (https=)
HU (1) HUE054075T2 (https=)
IL (2) IL299075A (https=)
MX (1) MX2017005152A (https=)
PL (1) PL3212230T3 (https=)
PT (1) PT3212230T (https=)
SG (2) SG10201913099YA (https=)
SI (1) SI3212230T1 (https=)
WO (1) WO2016069919A1 (https=)
ZA (2) ZA201702347B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963720C (en) * 2014-10-29 2024-05-14 Seattle Genetics, Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies
US12109346B2 (en) * 2015-03-27 2024-10-08 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
SI3464361T1 (sl) 2016-05-27 2022-01-31 Abbvie Biotherapeutics Inc. Protitelesa proti CD40 in njihove uporabe
CN110546164B (zh) 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
AU2019234828B2 (en) * 2018-03-13 2025-02-27 Hibercell, Inc. Beta glucan and CD40 agonist combination immunotherapy
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
ES3016535T3 (en) 2018-11-23 2025-05-09 Strike Pharma Ab Bi-specific conjugates
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
KR20220007849A (ko) * 2019-03-18 2022-01-19 스코어 파마, 인코포레이티드 푸코실화를 억제하기 위한 화합물 및 그의 사용 방법
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN114641310A (zh) * 2019-06-21 2022-06-17 德克萨斯大学系统董事会 治疗癌症和其他疾病的靶向α3β1整合素
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022072523A1 (en) 2020-09-30 2022-04-07 Seagen Inc. Uveal melanoma treatment using sea-cd40
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
TW202314247A (zh) 2021-05-25 2023-04-01 美商思進公司 量化抗cd40抗體之方法
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4377348A1 (en) 2021-07-30 2024-06-05 Seagen Inc. Treatment for cancer
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2025184665A1 (en) * 2024-03-01 2025-09-04 Immorta Bio, Inc. Senescence vaccine
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
ATE363290T1 (de) 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic Cd40 antagonist zur behandlung von psoriasis
WO2002011763A1 (en) 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
PT1391464E (pt) 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CA2609269C (en) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
EP1968636A4 (en) 2005-12-09 2010-06-02 Seattle Genetics Inc METHOD OF USE OF CD40 BONDING AGENTS
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
MX2010005080A (es) 2007-11-07 2010-07-28 Genentech Inc Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
WO2009094391A1 (en) * 2008-01-23 2009-07-30 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
US8163551B2 (en) * 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2963720C (en) * 2014-10-29 2024-05-14 Seattle Genetics, Inc. Dosage and administration of non-fucosylated anti-cd40 antibodies

Similar Documents

Publication Publication Date Title
JP2020050677A5 (https=)
Kohrt et al. Targeting CD137 enhances the efficacy of cetuximab
Bachanova et al. NK cells in therapy of cancer
US8206711B2 (en) Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
Tse et al. Antibody-based immunotherapy for ovarian cancer: where are we at?
Zhang et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia
JP2020508317A5 (https=)
JP2023071889A (ja) Ｔｉｇｉｔおよびｐｄ－１／ｔｉｇｉｔ結合分子
KR20170117113A (ko) 면역 관문 저해제와 조합한 플리나불린의 용도
Gall et al. T cells armed with anti-CD3× anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
RS54525B2 (sr) Sredstva i postupci za tretiranje dlbcl
WO2009064789A2 (en) Methods for detecting and monitoring circulating cancer stem cells
Saleh et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: clinical and immunological data
JP2019070056A (ja) 固形がんの治療剤
Shek et al. Pharmacogenetics of anticancer monoclonal antibodies
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
Song et al. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
Ureshino et al. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
Zhu et al. Natural killer cell engagers: from bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
Messaoudene et al. Patient’s natural killer cells in the era of targeted therapies: role for tumor killers
JP6156604B1 (ja) Ａｌｌｅｒｇｉｎ−１アンタゴニストによるがん免疫増強剤
MXPA06008942A (es) Inmunoglobulinas anti-moleculas de adhesion a celulas epiteliales(epcam).
Lamers et al. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re‐targeted by a bi‐specific monoclonal antibody
Rouanne et al. Pegylated engineered IL2 plus anti–PD-1 monoclonal antibody: the nectar comes from the combination
Carlo-Stella et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice